Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure.
Ventilator-associated pneumonia (VAP) is frequent in Intensive Care Unit (ICU) patients. In the specific case of patients treated with Veno-Arterial Extracorporeal Membrane Oxygenation Support (VA-ECMO), VAP treatment failures (VAP-TF) have been incompletely investigated.To investigate the risk fact...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5898723?pdf=render |
| _version_ | 1828367044024729600 |
|---|---|
| author | Adrien Bouglé Camille Bombled Dimitri Margetis Guillaume Lebreton Charles Vidal Marine Coroir David Hajage Julien Amour |
| author_facet | Adrien Bouglé Camille Bombled Dimitri Margetis Guillaume Lebreton Charles Vidal Marine Coroir David Hajage Julien Amour |
| author_sort | Adrien Bouglé |
| collection | DOAJ |
| description | Ventilator-associated pneumonia (VAP) is frequent in Intensive Care Unit (ICU) patients. In the specific case of patients treated with Veno-Arterial Extracorporeal Membrane Oxygenation Support (VA-ECMO), VAP treatment failures (VAP-TF) have been incompletely investigated.To investigate the risk factors of treatment failure (VAP-TF) in a large cohort of ICU patients treated with VA-ECMO, we conducted a retrospective study in a Surgical ICU about patients assisted with VA-ECMO between January 1, 2013, and December 31, 2014. Diagnosis of VAP was confirmed by a positive quantitative culture of a respiratory sample. VAP-TF was defined as composite of death attributable to pneumonia and relapse within 28 days of the first episode.In total, 152 patients underwent ECMO support for > 48h. During the VA-ECMO support, 85 (55.9%) patients developed a VAP, for a rate of 60.6 per 1000 ECMO days. The main pathogens identified were Pseudomonas aeruginosa and Enterobacteriaceae. VAP-TF occurred in 37.2% of patients and was associated with an increased 28-day mortality (Hazard Ratio 3.05 [1.66; 5.63], P<0.001), and VA-ECMO assistance duration (HR 1.47 [1.05-2.05], P = 0.025). Risk factors for VAP-TF were renal replacement therapy (HR 13.05 [1.73; 98.56], P = 0.013) and documentation of Pseudomonas aeruginosa (HR 2.36 [1.04; 5.35], P = 0.04).VAP in patients treated with VA-ECMO is associated with an increased morbidity and mortality. RRT and infection by Pseudomonas aeruginosa appear as strong risks factors of treatment failure. Further studies seem necessary to precise the best antibiotic management in these patients. |
| first_indexed | 2024-04-14T05:53:13Z |
| format | Article |
| id | doaj.art-49d8af3820d5482c91b6bf8eadfeeaf1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-14T05:53:13Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-49d8af3820d5482c91b6bf8eadfeeaf12022-12-22T02:09:02ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01134e019497610.1371/journal.pone.0194976Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure.Adrien BougléCamille BombledDimitri MargetisGuillaume LebretonCharles VidalMarine CoroirDavid HajageJulien AmourVentilator-associated pneumonia (VAP) is frequent in Intensive Care Unit (ICU) patients. In the specific case of patients treated with Veno-Arterial Extracorporeal Membrane Oxygenation Support (VA-ECMO), VAP treatment failures (VAP-TF) have been incompletely investigated.To investigate the risk factors of treatment failure (VAP-TF) in a large cohort of ICU patients treated with VA-ECMO, we conducted a retrospective study in a Surgical ICU about patients assisted with VA-ECMO between January 1, 2013, and December 31, 2014. Diagnosis of VAP was confirmed by a positive quantitative culture of a respiratory sample. VAP-TF was defined as composite of death attributable to pneumonia and relapse within 28 days of the first episode.In total, 152 patients underwent ECMO support for > 48h. During the VA-ECMO support, 85 (55.9%) patients developed a VAP, for a rate of 60.6 per 1000 ECMO days. The main pathogens identified were Pseudomonas aeruginosa and Enterobacteriaceae. VAP-TF occurred in 37.2% of patients and was associated with an increased 28-day mortality (Hazard Ratio 3.05 [1.66; 5.63], P<0.001), and VA-ECMO assistance duration (HR 1.47 [1.05-2.05], P = 0.025). Risk factors for VAP-TF were renal replacement therapy (HR 13.05 [1.73; 98.56], P = 0.013) and documentation of Pseudomonas aeruginosa (HR 2.36 [1.04; 5.35], P = 0.04).VAP in patients treated with VA-ECMO is associated with an increased morbidity and mortality. RRT and infection by Pseudomonas aeruginosa appear as strong risks factors of treatment failure. Further studies seem necessary to precise the best antibiotic management in these patients.http://europepmc.org/articles/PMC5898723?pdf=render |
| spellingShingle | Adrien Bouglé Camille Bombled Dimitri Margetis Guillaume Lebreton Charles Vidal Marine Coroir David Hajage Julien Amour Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. PLoS ONE |
| title | Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. |
| title_full | Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. |
| title_fullStr | Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. |
| title_full_unstemmed | Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. |
| title_short | Ventilator-associated pneumonia in patients assisted by veno-arterial extracorporeal membrane oxygenation support: Epidemiology and risk factors of treatment failure. |
| title_sort | ventilator associated pneumonia in patients assisted by veno arterial extracorporeal membrane oxygenation support epidemiology and risk factors of treatment failure |
| url | http://europepmc.org/articles/PMC5898723?pdf=render |
| work_keys_str_mv | AT adrienbougle ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT camillebombled ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT dimitrimargetis ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT guillaumelebreton ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT charlesvidal ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT marinecoroir ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT davidhajage ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure AT julienamour ventilatorassociatedpneumoniainpatientsassistedbyvenoarterialextracorporealmembraneoxygenationsupportepidemiologyandriskfactorsoftreatmentfailure |